Clinical Edge Journal Scan

Higher olive oil intake not linked to increased breast cancer risk


 

Key clinical point: According to an analysis of two large prospective US-based cohorts, the consumption of olive oil was not associated with an increased risk for breast cancer (BC) among women.

Major finding: C ompared with women who never or rarely consumed olive oil, those with the highest consumption of olive oil (>1/2 tablespoon/day or >7 g/day) did not report an increased risk of developing BC (hazard ratio 1.01; 95% CI 0.93-1.09).

Study details: Findings are from an analysis of two large prospective cohorts of women who were free of cancer at baseline, the Nurses’ Health Study (n = 71,330) and Nurses’ Health Study II (n = 93,295), of whom 9638 women developed invasive BC after 3,744,068 person-years of follow-up.

Disclosures: This study was supported by the US National Institutes of Health and other sources. The authors declared no conflicts of interest.

Source: Romanos-Nanclares A et al. Consumption of olive oil and risk of breast cancer in U.S. women: Results from the Nurses' Health Studies. Br J Cancer. 2023 (Jun 13). Doi: 10.1038/s41416-023-02306-x

Recommended Reading

Interrupting radiotherapy for TNBC linked to worse survival
MDedge Hematology and Oncology
New global initiative aims to reform cancer trials and care
MDedge Hematology and Oncology
U.S. mammogram update sparks concern, reignites debates
MDedge Hematology and Oncology
Benefit of regional nodal irradiation remains questionable in HR+/ERBB2− node-positive BC
MDedge Hematology and Oncology
Increased contralateral BC risk after adjuvant radiotherapy in germline-BRCA2 pathogenic variants
MDedge Hematology and Oncology
Receiving anthracyclines raises risk for myeloid neoplasms in BC patients
MDedge Hematology and Oncology
Positive nodal status and stage T4 tied to worsened long-term prognosis in HER2+ breast cancer
MDedge Hematology and Oncology
Recurrence-free survival outcomes worse in HR− BC
MDedge Hematology and Oncology
Six cycles of chemotherapy can be an alternative to eight cycles in breast cancer
MDedge Hematology and Oncology
Breast-conserving therapy bests mastectomy in improving survival outcomes regardless of nodal status
MDedge Hematology and Oncology